July 2, 2019 10:52 AM EDTUpdated 11:13 AM
News Briefing

Got­tlieb re­buts Sci­ence re­port on plum­met­ing FDA in­spec­tions; Lib­tayo wins EMA and NICE en­dorse­ment

Natalie Grover

Reporter

→ The jour­nal Sci­ence on Tues­day pub­lished a re­port that con­clud­ed the FDA’s com­pli­ance and en­force­ment ac­tions have plum­met­ed since Don­ald Trump took of­fice …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times